Navigation Links
Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
Date:1/8/2010

TAIZHOU, China, Jan. 8 /PRNewswire-Asia/ -- The Jiangsu Government's Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com ), is working with Jiangsu University and Nanjing University's Drum Tower Hospital to fulfill the grant's requirements.

This grant marks the start of the second stage of Beike's stem cell engineering industrialization project. The project's first phase began in May 2008, when Beike opened a 1,800 square-meter stem cell bank in Taizhou's China Medical City district. In the second phase, the bank will be used as a library for storing and indexing hUC-MSC samples. In April 2009, Beike broke ground on its 20,000 square-meter Stem Cell Regenerative Medicine Industrial Complex, the world's largest stem cell storage and processing facility. Beike will use a portion of the Jiangsu Technological Achievements Transformational Grant to outfit this complex with over 80 specialized pieces of equipment including fully automated enzyme immunoassay analysis systems, carbon dioxide incubators, and cell viability analyzers.

The grant's three-year objectives are to systematically develop hUC-MSC technology and its medical application from "bench-to-bedside" - from harvesting, to laboratory modeling, through clinical trials, and finally clinical applications in treating Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS) and other degenerative diseases. In support of this effort, Beike will provide the facilities, equipment, management framework and certain proprietary clinical stem cell technologies for the project. Nanjing University Medical School's renowned Drum Tower Hospital will be responsible for administering the human trials while Jiangsu University will bring its vast biological research and development resources to the production and animal study phases of the project.

Dr. Sean Hu, CEO and Chairman of Beike Biotechnology, commented on the collaboration saying, "As Asia's leader in stem cell technology and its applications, Beike is proud to partner with two of Jiangsu's top medical universities - both already established as leaders in stem cell technology and application. I am confident that with continued support from both Jiangsu Province and China's government, this collaboration will continue to produce groundbreaking work in the field of stem cells."

The Drum Tower Hospital will be responsible for the human clinical trials enlisting 200 patients. Dr. Sun Lingyun, the Director of the Hospital's Rheumatology and Immunology Department, will direct the 140-patient Systemic Lupus Erythematosus clinical trial while Dr. Xu Yun, Director of the Hospital's Neurology Department, will oversee the 60-patient Multiple Sclerosis trial.

"I have been studying stem cells since 1997 and have seen their healing potential in animal studies and in human subjects," stated Dr. Sun, commenting on his previous experience with stem cells. "This grant will help solidify China Medical City as one of the primary hubs for stem cell technology research. The studies conducted under this grant will be groundbreaking in the large number of patients they include."

Dr. Sun Lingyun has worked extensively with stem cell technology both in the laboratory and clinically. This project will build on his earlier publication in the journal Stem Cells, entitled "Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus in Mice and Humans."

With encouraging outcomes already apparent for MS and SLE, Jiangsu University's next task will be to create animal models for testing hUC-MSCs potential in other disorders such as brain injury, spinal cord injury, liver disease and kidney damage. Jiangsu University has already made advances in hUC-MSC separation, detection, purification, amplification and quality control. As part of this grant, the university will be researching hUC-MSC growth, differentiation characteristics, identification standards and serum-free medium studies.

About China Medical City

Jiangsu Province is the number one location for China's medical industry based on the revenue generated over the past five years. The city of Taizhou is fast becoming Jiangsu's leading biotech location, with over 35% annual growth since 2004. China Medical City enjoys a prime 25-square kilometer location in the heart of Taizhou City. The district was established by the Chinese Government in 2005 and has active support from the local government. It embodies China's goal of streamlining the pharmaceutical and medical materials industry by concentrating all medical services and support in one central location.

About Beike Biotechnology Company Limited

Beike Biotechnology (http://www.beikebiotech.com ) is China's leading biotechnology company. Its scientists have been focused on the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products from umbilical cord, cord blood, and bone marrow stem cells. Beike's unique processing technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve pathologies.

    For more information, please contact:

     T. Gutmann
     Shenzhen Beike Biotechnology Company, Ltd.
     Shenzhen Hi-Tech Industrial Park
     Tel:   +86-755-8630-9200
     Email: info@beikebiotech.com
     Web:   http://www.beikebiotech.com

SOURCE Beike Biotechnology Company Limited

RELATED LINKS
http://www.beikebiotech.com

'/>"/>

SOURCE Beike Biotechnology Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India
2. Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future Pipeline
3. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
4. Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China
5. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
6. Stem Cell Leader Beike Biotech and Chinas Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory
7. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million
10. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
11. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... The leading ... of its most experienced veterinary clients have treated over 100 of their own patients ... technology to provide the highest level of care for their patients. , The ...
(Date:5/20/2016)... ... May 20, 2016 , ... The recent recall by Costco and Trader ... Safety News on May 12, 2016(1), demonstrates the need for faster and more cost ... biotech firm, PathSensors, Inc. , PathSensor’s latest solution uses a biosensor ...
(Date:5/19/2016)... , May 19, 2016 ... will fully recover given the relentless pressures in pricing ... sure in the investors circle though - numerous opportunities ... Ahead of today,s session, ActiveWallSt.com,s presents four names in ... ), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), ...
(Date:5/19/2016)... May 19, 2016 - I ... orale durante il 52 ° ...    - Le conclusioni dello studio indicano ... pazienti trattati, di cui il 90% presenta una d ... o più. Il settantadue per cento dei pazienti ha riscontrato ...
Breaking Biology Technology:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):